99 related articles for article (PubMed ID: 10509009)
21. [Serum proteomics in patients with RAEB myelodysplastic syndromes].
Zhong LY; Liu TH; Li YQ; Geng SX; Lu ZS; Weng JY; Wu SJ; Luo CW; Du X
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Sep; 29(9):1799-801. PubMed ID: 19778794
[TBL] [Abstract][Full Text] [Related]
22. Increased levels of soluble tumor necrosis factor receptors in patients with aplastic anemia and myelodysplastic syndrome.
Shinohara K; Muraki K; Ota I; Nawata R; Oeda E; Takahashi T
Am J Hematol; 2000 Dec; 65(4):326-7. PubMed ID: 11074567
[No Abstract] [Full Text] [Related]
23. Language and the clonal myeloid diseases.
Lichtman MA
Blood; 2002 Jan; 99(2):725-6. PubMed ID: 11799968
[No Abstract] [Full Text] [Related]
24. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.
Selleri C; Maciejewski JP; Catalano L; Ricci P; Andretta C; Luciano L; Rotoli B
Cancer; 2002 Nov; 95(9):1911-22. PubMed ID: 12404285
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes.
Matsui WH; Brodsky RA; Smith BD; Borowitz MJ; Jones RJ
Leukemia; 2006 Mar; 20(3):458-62. PubMed ID: 16437138
[TBL] [Abstract][Full Text] [Related]
26. Flow cytometric evaluation of circulating CD34+ cell counts and apoptotic rate in children with acquired aplastic anemia and myelodysplasia.
Timeus F; Crescenzio N; Doria A; Foglia L; Linari A; Giaccone M; Pastore G; di Montezemolo LC; Ramenghi U; Saracco P
Exp Hematol; 2005 May; 33(5):597-604. PubMed ID: 15850838
[TBL] [Abstract][Full Text] [Related]
27. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
28. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis.
Elghetany MT; Hudnall SD; Gardner FH
Haematologica; 1997; 82(1):21-4. PubMed ID: 9107077
[TBL] [Abstract][Full Text] [Related]
29. Undetectable peripheral blood CFU-GM as a prognostic indicator in myelodysplastic syndrome.
Tennant GB; Jacobs A
Leuk Res; 1988; 12(11-12):961-2. PubMed ID: 3216676
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood chromosome aberrations in MDS.
White AD; Jacobs A
Cancer Genet Cytogenet; 1992 Apr; 59(2):167-72. PubMed ID: 1581882
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
[TBL] [Abstract][Full Text] [Related]
32. Levels of soluble Fas ligand in myocarditis.
Toyozaki T; Hiroe M; Tanaka M; Nagata S; Ohwada H; Marumo F
Am J Cardiol; 1998 Jul; 82(2):246-8. PubMed ID: 9678301
[TBL] [Abstract][Full Text] [Related]
33. Type I and type II T-cell profiles in aplastic anemia and refractory anemia.
Tsuda H; Yamasaki H
Am J Hematol; 2000 Aug; 64(4):271-4. PubMed ID: 10911379
[TBL] [Abstract][Full Text] [Related]
34. Fas-Fas ligand system in the peripheral blood of patients with renal diseases.
Sato M; Konuma T; Yanagisawa N; Haizuka H; Asakura H; Nakashima Y
Nephron; 2000 Jun; 85(2):107-13. PubMed ID: 10867515
[TBL] [Abstract][Full Text] [Related]
35. [Expression of three kinds of GPI-anchor proteins in paroxysmal nocturnal hemoglobinuria, aplastic anemia and myelodysplastic syndromes patients and their clinical implications].
Dong XY; Xu CG; Sun GR; Zhang T; Peng J
Zhonghua Xue Ye Xue Za Zhi; 2004 Apr; 25(4):198-201. PubMed ID: 15182554
[TBL] [Abstract][Full Text] [Related]
36. [Expressive changes of CD4(+)T cell subset transcription factors in patients with aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia and their clinical significances].
Feng XM; Xu HZ; Zhang JY; Yin DM; Liu MM; Sui XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1038-42. PubMed ID: 25130824
[TBL] [Abstract][Full Text] [Related]
37. Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.
Fontana L; De Sanctis G; De Rossi G; Bottari V; Petti MC; Ensoli F; Pasqualetti D; Mandelli F
Acta Haematol; 1989; 82(1):1-6. PubMed ID: 2505468
[TBL] [Abstract][Full Text] [Related]
38. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons.
Hosaka N; Oyaizu N; Kaplan MH; Yagita H; Pahwa S
J Infect Dis; 1998 Oct; 178(4):1030-9. PubMed ID: 9806031
[TBL] [Abstract][Full Text] [Related]
39. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.
Tamura H; Dan K; Yokose N; Iwakiri R; Ohta M; Sakamaki H; Tohyama K; Kondo A; Hyodo H; Nakamura K; Yamashita T; Elisseeva OA; Oka Y; Oji Y; Sugiyama H; Ogata K
Leuk Res; 2010 Aug; 34(8):986-90. PubMed ID: 20031209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
